Vol.16, No. 63, Spring 2023
Anagha Tendulkar, is an In-house counsel at Cipla Limited, India. Her role majorly focusses on activities relating to ANDA litigations and includes pre-litigation, in- litigation and post- litigation strategizing for early product launch. Other activities include portfolio selection, priming on legal and regulatory hurdles, strategic decision making, due diligence for small molecules and biologicals, etc.
She has about 15 years of experience in this field. Prior to joining Cipla Limited, she was an In- house counsel at Panacea Biotech, India. Her role was to manage various IP related activities for the organization, including identifying early market entry opportunities, patent due diligences, design- around strategies, patent drafting and prosecution.
â€¢ Speaker- National Seminar organized by PES, Modern College of Pharmacy, India- â€œPatent Basics and Overview of Generic Drugs in USâ€
â€¢ Invited to address on â€œPatents- an insightâ€ at a symposium, Modern College of Pharmacy, India
â€¢ "Induced Infringement under US Patent Law" Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 15, No. 59, Spring 2022, 1
â€œWritten Description Requirement of Patentabilityâ€ Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 15, No. 58, Winter 2022, 1
. â€œBlocking Effect of the Blocking Act?â€ Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 14, No. 55, Spring 2021, 1
â€¢ â€œDemethylation and Transcriptional activation of genes involved in metastasis of pancreatic cancer by Methyl-CpG-binding domain 2. â€ Tendulkar S. , Ou J. -N. , Tendulkar A. , Szyf M. Pharmacological research day (PRD) annual meeting Montreal, CANADA, Jun 2006.
â€¢ â€œDemethylation and Transcriptional activation of genes involved in metastasis of pancreatic cancer by Methyl-CpG-binding domain 2. â€ Tendulkar S. , Ou J. -N. , Tendulkar A. , Szyf M. AACR, Washington D. C. , Apr 2006.
â€¢ â€œMetabolic engineering of Yeast: Yarrowia lipolyticaâ€ Tendulkar A. , Bhave S. Chattoo B. B. , International meeting - â€œYeast 2003â€, IMTECH, Chandigarh, India, Feb 2003.
â€¢ LL. B, University of Mumbai
â€¢ Registered Patent Agent, India
â€¢ P. G. Diploma in Patent Management, AIPS, Mumbai
â€¢ Research Associate, Department of Pharmacology, McGill University, Canada
â€¢ Research Fellow, MSU, Baroda, India
â€¢ Post-graduation, University of Mumbai (Microbiology/ Biotechnology)
â€¢ Qualified- Joint All- India CSIR-UGC Test, CSIR, New Delhi, India
â€¢ Qualified- State Eligibility Test, University of Pune, Maharashtra, India
â€¢ Awarded Certificate of merit, Post-graduation, University of Mumbai
Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. It primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Its portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Ciplaâ€™s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Vol.16, No. 63, Spring 2023